"Anti-Obesity Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.
| Descriptor ID |
D019440
|
| MeSH Number(s) |
D27.505.954.427.140
|
| Concept/Terms |
Anti-Obesity Agents- Anti-Obesity Agents
- Agents, Anti-Obesity
- Anti Obesity Agents
- Anti-Obesity Drugs
- Anti Obesity Drugs
- Drugs, Anti-Obesity
- Antiobesity Drugs
- Drugs, Antiobesity
- Antiobesity Agents
- Agents, Antiobesity
Weight-Loss Agents- Weight-Loss Agents
- Agents, Weight-Loss
- Weight Loss Agents
- Weight-Loss Drugs
- Drugs, Weight-Loss
- Weight Loss Drugs
|
Below are MeSH descriptors whose meaning is more general than "Anti-Obesity Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Obesity Agents".
This graph shows the total number of publications written about "Anti-Obesity Agents" by people in this website by year, and whether "Anti-Obesity Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 1 | 3 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Obesity Agents" by people in Profiles.
-
Vest AR, Chan M, Deswal A, Givertz MM, Lekavich C, Lennie T, Litwin SE, Parsly L, Rodgers JE, Rich MW, Schulze PC, Slader A, Desai A. Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. J Card Fail. 2019 May; 25(5):380-400.
-
Hoang TT, Agopian AJ, Mitchell LE. Maternal Use of Weight Loss Products and the Risk of Neural Tube Defects in Offspring: A Systematic Literature Review. Birth Defects Res. 2018 01 15; 110(1):48-55.
-
Hong K, Herrmann K, Dybala C, Halseth AE, Lam H, Foreyt JP. Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clin Obes. 2016 Oct; 6(5):305-12.
-
Samson SL, Garber AJ. Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. Best Pract Res Clin Endocrinol Metab. 2016 06; 30(3):357-71.
-
Taylor SA, Himes R, Hastings E, Garland B. Gastrointestinal Conditions in the Obese Patient. Adolesc Med State Art Rev. 2016; 27(1):93-108.
-
Garber AJ. ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES. Endocr Pract. 2015 Jun; 21(6):634-44.
-
Patel SS, Beer S, Kearney DL, Phillips G, Carter BA. Green tea extract: a potential cause of acute liver failure. World J Gastroenterol. 2013 Aug 21; 19(31):5174-7.
-
Gulvady AA, Ciolino HP, Cabrera RM, Jolly CA. Resveratrol inhibits the deleterious effects of diet-induced obesity on thymic function. J Nutr Biochem. 2013 Sep; 24(9):1625-33.
-
Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun. 2013; 4:2384.
-
Moyer VA. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012 Sep 04; 157(5):373-8.